Stem Cell Therapy in Panama: The Regulatory Gap Patients Must Know

Introduction: The Gap Between Marketing and Medicine

Panama is often marketed as one of the world’s most “progressive” destinations for stem cell therapy. Clinic websites, medical tourism agencies, and social media campaigns describe a forward-thinking regulatory environment, modern facilities, and treatments for nearly every chronic condition. Panamanian law tells a far narrower story.

The central finding of this article is simple. Only hematopoietic stem cell transplantation for blood disorders has solid scientific and legal backing in Panama. Most advertised orthopedic, anti-aging, autoimmune, and neurological “stem cell therapies” remain experimental. On paper, they require clinical trial oversight. In practice, they operate largely without it.

Rather than relying on promotional claims, this article draws on primary legal sources: Law 3 of 2010, Executive Decree 2 of 2013, Executive Decree 179 of 2018, Law 419 of 2024, and Law 462 of 2025. It also uses peer-reviewed literature, guidance from the International Society for Stem Cell Research (ISSCR), and documented controversies.

The intended reader is a patient, or a family member, actively researching stem cell treatment in Panama who needs an evidence-based resource before making a decision. The timing matters. As of 2026, according to a peer-reviewed analysis of the Panamanian system, no stem cell clinical trial protocols have been submitted to Panama’s National Research Bioethics Committee since 2018, even as the commercial industry continues to thrive.

What Is Actually Legal: Hematopoietic Stem Cell Transplantation

Hematopoietic stem cell transplantation, commonly known as bone marrow transplantation, replaces a patient’s damaged or diseased blood-forming cells with healthy ones. The cells may come from the patient (autologous) or from a donor (allogeneic). This procedure has decades of clinical research behind it and is a standard treatment for leukemias, lymphomas, and other hematological diseases worldwide.

In Panama, it is also the only stem cell use with official recognition. A 2026 peer-reviewed article, Unproven stem cell-based interventions marketed as treatments in Panama: An urgent call for enforcement actions, states that under Ministry of Health (MoHP) guidelines, the only currently accepted clinical practice involving stem cells is the transplantation of hematopoietic tissue and cells, autologous and allogeneic, for hematological diseases. Any other stem cell use should be viewed as experimental and subjected to evaluation in clinical trials.

HSCs vs. MSCs: Why the Terminology Matters

Patients frequently encounter two terms that sound similar but are clinically very different:

• Hematopoietic stem cells (HSCs): Found in bone marrow, peripheral blood, and cord blood, these cells generate blood and immune cells. Their use in transplantation for blood disorders is well established.
• Mesenchymal stem cells (MSCs): Found in tissues such as fat, bone marrow stroma, and umbilical cord tissue, these cells are being studied for many uses, but their benefit for most conditions has not been proven in rigorous trials.

Most treatments marketed to international patients in Panama use MSCs, not HSCs. That distinction places them outside the only legally recognized treatment category.

Tracing Panama’s Regulatory Evolution: A Primary-Source Timeline

Some competitor content cites outdated or non-existent authorities, including references to a “CONCYTEC” stem cell regulator or a vague “Health Act.” The following timeline is built from the actual statutes and decrees that shape Panama’s framework.

Law 3 of 2010: The Foundational Transplant Law

Law 3 of 2010 regulated the transplantation of anatomical components, including human tissue and cells. However, it did not specifically address stem cell research or the development of advanced therapy medicinal products.

This omission created an early legal vacuum. Without rules tailored to stem cell interventions, clinics found room to market treatments that fell between the categories the law contemplated.

Executive Decree 2 of 2013: The First Stem Cell-Specific Rule

Executive Decree No. 2 of January 2013 was the first regulation aimed specifically at stem cells. It set guidelines for establishing clinical centers authorized to provide stem cell interventions.

Its critical weakness was that it did not clearly distinguish between approved and unproven stem cell interventions. A clinic could be authorized as a center without the specific therapies it offered being validated. That ambiguity remains the foundation of much clinic marketing today, where facility authorization is presented as if it were treatment approval.

Executive Decree 179 of 2018: The Current Framework

Executive Decree 179 of June 8, 2018 established the current framework. Under it, stem cells used in clinical trials are considered Advanced Therapy Medicinal Products (ATMPs), regulated by the National Directorate of Pharmacy and Drugs (NDPD). The NDPD coordinates their use for research and issues ATMP Use Permits.

In theory, this created a clear pathway: research-stage stem cell use would require a permit, a bioethics-reviewed protocol, and regulatory supervision.

In practice, the enforcement gap is stark. The 2026 peer-reviewed analysis notes that local NDPD processes and capacities for implementing and issuing ATMP permits require strengthening to enable effective oversight. More striking still, since 2018, no stem cell-related clinical trial protocols have been submitted to the National Research Bioethics Committee (NRBC), and no ATMP applications have been submitted to the NDPD. The regulatory pathway exists, yet the industry has not used it.

Law 419 (2024) and Law 462 (2025): Modernizing Pharmaceutical Oversight

According to the International Bar Association’s healthcare law survey on Panama, the principal statutes governing the import, distribution, sale, and export of therapeutic products are:

• Law 419 of February 1, 2024, regulating medicines and other products for human health, as well as medical devices
• Law 462 of March 18, 2025, which modifies Law 419
• Executive Decree 27 of May 10, 2024, which implements Law 419

The ATMP permit framework now rests on both Decree 179 and Law 419. Most legal commentary treats these newer laws as generic pharmaceutical reforms. For stem cell patients, their significance is that they reinforce the legal structure around ATMPs without resolving the core problem: rules exist, but they are not being applied to the commercial clinics marketing unproven treatments.

One firm boundary holds throughout this framework. As the Law Library of Congress comparative report notes, Panama does not allow the creation of human embryos to obtain stem cells.

The Twice-Rejected Attempts to Legalize Commercial Stem Cell Sales

A detail rarely mentioned in promotional content is that industry-aligned efforts have twice tried to formalize the commercial sale of unproven treatments.

• 2022: A draft decree sought to enable commercialization of MSC-based interventions on the strength of preliminary Phase I data. Phase I trials are designed mainly to assess safety in small groups, not to establish that a treatment works.
• 2023: Another draft decree sought to authorize the therapeutic use of unproven MSC interventions.

Panama’s National Research Bioethics Committee recommended against both proposals. The Ministry of Health supported that position, and neither decree was approved.

This history matters. What clinics present as a “progressive” environment is, legally, one of tolerance rather than approval. Regulators have twice been asked to legitimize these treatments, and they have twice declined.

What’s Actually Being Marketed vs. What’s Approved

Panamanian clinics commonly market stem cell interventions for:

1. Musculoskeletal and orthopedic disorders (joints, spine, sports injuries)
2. Neurological conditions (including autism, multiple sclerosis, and spinal cord injury)
3. Autoimmune diseases
4. Cardiovascular disease
5. Cosmetic and anti-aging applications

These offerings primarily use mesenchymal stem cells, often derived from umbilical cord tissue. They fall outside the hematopoietic, blood-disorder category that Panama’s health authorities recognize. Peer-reviewed sources state plainly that the marketing of unproven stem cell interventions outside a research context or an approved hematological treatment remains a concern in Panama.

The pattern is not new. Before Decree 179, numerous advertisements featuring celebrity testimonials appeared in local newspapers, travel magazines, and social media. That visible regulatory gap helped prompt the 2018 decree. Years later, the marketing environment persists largely unchanged.

Case Study: The Stem Cell Institute and the Retracted Autism Study

The Stem Cell Institute in Panama City, founded by Neil Riordan, is one of the country’s most prominent private clinics. It uses umbilical cord tissue-derived MSCs to treat a range of conditions.

Its autism research illustrates how scientific branding can outpace scientific evidence. A 2019 autism trial associated with the clinic drew scrutiny after reporting revealed that participating families were charged substantial fees across their visits. Critics described the study as “pay-to-participate,” with financial conflicts of interest that had not been disclosed. As reported by The Transmitter (formerly Spectrum), the paper was retracted.

An independent fact-check published by stem cell biologist Paul Knoepfler on The Niche concluded that there are no strong data supporting the clinic’s claims, particularly on autism. He noted that the most rigorous study to date, conducted at Duke, suggested no consistent benefit, and that the procedures carry definite risks along with significant costs.

The lesson for patients is not limited to one clinic. Published papers, research-style language, and a polished brand can create an impression of validated science. Only independent, conflict-free, peer-reviewed evidence actually provides it.

Panama’s Enforcement Gap vs. Stricter Jurisdictions

In the United States, many of the procedures offered in Panama could not legally take place. The FDA permits donor stem cells only for cancers or immune disorders, with narrow research exceptions, citing documented risks of blindness, tumor formation, and bacterial infections.

That stricter stance has helped turn jurisdictions with more relaxed policies, notably Panama and the Cayman Islands, into hubs for luxury stem cell tourism.

The consequences are poorly tracked. An FDA spokesperson told the San Francisco Standard that the agency is aware of Americans traveling abroad for unapproved stem cell therapies but that its researchers “do not track adverse effects.” Patients therefore face a data void: there is no systematic record of how people fare after these treatments overseas.

Regulatory gaps are not unique to Panama. The same reporting cites roughly 2,754 unlicensed stem cell clinics operating in the United States, where treatments have been linked to blindness, infections, and death. Oversight is minimal: in 2024, the FDA issued a total of 13 warning letters. The problem is global, but patients considering Panama must navigate it actively rather than assume a foreign clinic has been vetted.

Documented Risks of Unproven Stem Cell Interventions

Medical literature, including a Canadian Medical Association Journal article that identified Panama as an active marketing destination, documents serious complications from unregulated stem cell interventions worldwide:

• Meningitis following injections
• Tumor formation, including a case in which a boy in Russia developed brain and spinal tumors after injections of fetal neural stem cells
• Serious lesions following a stem cell transplant

A public-health expert quoted in that literature summarized the core problem: “There’s no proof of safety and efficacy. The quality of facilities varies. The protocols are poorly documented and not available to the patients. Even in the best-case scenarios, the doctor doesn’t know whether it’s safe or efficacious because of a lack of data.”

The ISSCR’s 2024 patient guide reinforces this. The organization states that it is increasingly concerned by clinics marketing and administering stem cell treatments that have not been tested for safety or approved by regulators, and that the majority of these “treatments” are unproven and have the potential to cause harm.

Beyond clinical complications, patients should weigh practical risks:

• Follow-up care: Complications may appear after returning home, where local physicians may have no records of the protocol used.
• Legal recourse: Pursuing a malpractice claim in a foreign jurisdiction is difficult, costly, and uncertain.
• Insurance: Experimental procedures obtained abroad are generally not covered, and treatment of resulting complications may also face coverage disputes.

The Cost Transparency Problem (Without the Guesswork)

Publicly available cost information for stem cell treatment in Panama varies enormously across sources and clinics. Figures differ in whether they include laboratory testing, hospital fees, travel, accommodation, and the number of sessions, making them effectively impossible to compare.

That inconsistency is itself a warning sign. Without official, approved clinical protocols, there is no standardized basis for what a treatment consists of, and therefore no standardized basis for what it should cost. The pricing confusion reflects the same regulatory gap described throughout this article.

Patients should:

• Treat any quote as clinic-specific and non-comparable until they understand exactly what it covers
• Request an itemized written estimate directly from the provider
• Disregard third-party marketing figures, which are often outdated or unverifiable
• Ask what happens, financially and medically, if complications arise

How Patients Can Vet a Panama Stem Cell Clinic

Drawing on ISSCR guidance and Panama’s legal framework, patients can use the following checklist:

1. Ask whether the treatment is part of a registered clinical trial. If so, request the trial registration number and verify it independently.
2. Request the ATMP Use Permit or NRBC-approved protocol. Under Decree 179, research-stage stem cell use requires these. Given that no applications have been submitted since 2018, a clinic’s inability to produce them is highly informative.
3. Check the indication. Confirm whether the condition matches the hematopoietic, blood-disorder category with established evidence. If not, the treatment is experimental.
4. Separate facility accreditation from treatment validity. Punta Pacifica Hospital in Panama City, affiliated with Johns Hopkins Medicine International, holds JCI accreditation, which reflects strong hospital quality and safety systems. Accreditation of this kind evaluates facilities, not the efficacy of a specific experimental stem cell protocol.
5. Request credentials and data. Ask for physician qualifications and published, peer-reviewed outcome data. Testimonials are not evidence.
6. Review informed consent carefully. The consent document should explicitly acknowledge the treatment’s experimental status and known risks.
7. Consult public records. Where available, check NRBC and NDPD records to confirm whether a clinic’s protocol has ever been submitted for bioethics review.
8. Get an independent second opinion. A specialist in the patient’s home country, with no financial stake in the decision, can assess whether the proposed intervention makes medical sense.

Conclusion: Informed Decisions in an Unregulated Market

Panama’s legal and scientific backing for stem cell therapy is robust in one area only: hematopoietic stem cell transplantation for blood disorders. The broader commercial stem cell industry operates in a gray zone of tolerance rather than approval.

The pattern across more than a decade is consistent. Regulatory intent, expressed through Decree 179 and Laws 419 and 462, has been repeatedly outpaced by enforcement failure. Zero stem cell trial protocols have been submitted since 2018, and two attempts to legalize commercial sales were rejected. Peer-reviewed researchers in Panama have called for urgent enforcement action against what they describe as unscrupulous businesses.

Marketing claims, accreditation badges, and testimonials are not substitutes for clinical trial data, bioethics approval, or peer-reviewed evidence. A patient who understands this regulatory gap is best positioned to make a genuinely safe choice, whether that means pursuing legitimate hematopoietic treatment, enrolling in a verifiable trial, or declining unproven interventions altogether.

Next Steps: Questions to Bring to Any Consultation

Before booking a consultation or procedure, patients should work through the vetting checklist above and bring these questions to any provider:

• Is this treatment approved for my condition by Panama’s Ministry of Health?
• Is it part of a registered clinical trial, and can I see the ATMP Use Permit and NRBC approval?
• What peer-reviewed, independently published data support this protocol?
• What exactly is included in the cost, and what happens if I experience complications?
• Who will provide follow-up care after I return home?

Patients should also seek independent medical and legal advice before traveling, and consult official sources, including the MoHP, NDPD, and NRBC, along with internationally recognized bodies such as the ISSCR, for current guidance.

Finally, this should be treated as an ongoing research process rather than a single decision. Regulations, enforcement priorities, and clinic offerings can change quickly. Revisiting primary sources before every major step remains the most reliable safeguard available.